A Blog by AMCP CEO Susan Cantrell


AMCP_Beyond 
 

  


AMCP Celebrates Early Win: FDA Issues Draft Guidance to Improve Communications Between Biopharmaceutical Companies and Population Health Decision Makers

 

February 1, 2017 

Sometimes the best laid plans are upended when you least expect it!

In mid-January, the FDA released draft guidance to facilitate the sharing of information between biopharmaceutical companies and population health decision makers. To say we were pleasantly surprised is an understatement. We had designated this issue as one of our top advocacy priorities for 2017, and were prepared to work hard throughout the year to convince FDA officials and lawmakers of the need to issue guidance.

And now our plans have shifted, but we are not complaining! We have a starting point to make the case that the draft provisions should be finalized to provide the clarity we need.

The draft guidance, issued Jan. 18, largely mirrors consensus recommendations that AMCP developed during two multi-stakeholder meetings last year on the sharing of information on marketed and pipeline products. And we’re proud to note it comes only a few short weeks after we issued our last set of recommendations.

The long-awaited guidance — some components nearly 20 years in the making — clarifies how manufacturers and decision makers can proactively share clinical and economic information on marketed products, as well as on therapies awaiting FDA approval. It specifies clearly what types of information may be shared, with whom and under what conditions. This is crucial because laws and regulations have long placed high barriers on the sharing of any information that is not contained in an FDA-approved label.

But times have changed. Today’s pace of innovation, along with the high costs of many specialty medications, compels decision makers to take an earlier and deeper look at the value of new medicines.

That is why this guidance is so important. It gives decision makers access to information they need to make better coverage decisions for millions of Americans. And it gives manufacturers the confidence they need to initiate the sharing of information.

That was the clarion call that came out of AMCP’s first partnership forum: FDAMA Section 114—Improving the Exchange of Health Care Economic Data. Section 114 of the 1997 Food and Drug Administration Modernization Act (FDAMA) was designed as regulatory safe harbor for dissemination of information, but was little used due ambiguity in its wording and lack of implementing guidance. The guidance adopted many of the forum’s recommendations.

Additionally, the guidance for the first time provides assurances around the proactive exchange of information on products before FDA approval. We’re delighted that this section of the guidance includes many of the recommendations by AMCP’s second stakeholder partnership forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval. The clarification here will help decision makers develop more accurate financial forecasts around the overall benefit, and expedite coverage decisions immediately upon FDA approval, particularly for emerging therapies granted breakthrough designation.

Academy members and other stakeholders have been waiting for this guidance on post-approval communications for a long time. AMCP members raised this issue as a particular concern last year, and asked us to take action. We were happy to do so. And whether the guidance was expedited as part of the Obama Administration’s final flurry of activity, we are glad it has finally arrived. We also firmly believe this guidance is on sound footing, and will be upheld by the Trump Administration.

AMCP is proud to have taken the lead on this issue. In the coming year, we will work to ensure the guidance is understood and adopted by stakeholders throughout managed care pharmacy arena. I’d like to give my staff a well-deserved pat on the back for the hard work in making this happen.

______

The FDA draft guidance, “Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers,” is available http://bit.ly/2jnFU1O. AMCP’s consensus recommendations were published in AMCP’s Journal of Managed Care & Specialty Pharmacy. Read recommendations on marketed products at http://bit.ly/2jzMUef, and PIE at http://bit.ly/2jjjkHv. 


Susan A. Cantrell, RPh, CAE is CEO of the Academy of Managed Care Pharmacy 


  


Making PIE to Better Serve Patients

 

January 11, 2017 

Let’s imagine you’re a big city mayor and it’s time to order a new fleet of police cars for next year. Applying due diligence, you set out to compare various models from a variety of manufacturers. ... Read more 


  


Century Cures Act Advances AMCP's FDAMA Goals, Improves Value-Based Communications Between Manufacturers and Managed Care Pharmacy

 

December 22, 2016 

Who says Congress can’t get anything done…and with bipartisan support to boot? With impressive speed and purpose, the House and Senate overwhelmingly passed the 21st Century Cures Act in the waning days of the 114th Congress, followed by President Obama’s prompt signature. ... Read more 


  


Pharmacy Profession Comes Together to Help Document and Improve Patient Outcomes Through Medication Therapy Management

 

November 7, 2016 

People can accomplish remarkable things when they work toward a common goal. That’s what happened recently when a diverse group of pharmacy stakeholders gathered to develop standardized terms for medication therapy management (MTM) services. ... Read more 


  


AMCP really knows how to get things done!

 

October 13, 2016 

Not long ago a respected individual in the health care arena told one of my senior staff: “Compared to other associations I work with, AMCP really knows how to get things done.” You cannot imagine how proud I felt ... Read more 


  


AMCP Volunteers Are a Happy Lot

 

September 20, 2016 

There are many ways to measure the health and vitality of a professional association. The most crucial indicators, I’ve found, center on the engagement of an organization’s volunteers. This can be measured in the number of volunteer opportunities provided, the number of members who sign up, and the level of satisfaction they get from volunteering. ... Read more 


     


The Post Cites Pharmacists’ Expanding Role on Medical Teams

 

August 26, 2016 

Last week I saw a headline that jumped off the page: “America’s other drug problem: Giving the elderly too many prescriptions” (Washington Post, Aug. 15). I couldn’t read it fast enough and encourage members to do likewise, as it highlights two of the most important developments in health care. ... Read more 


       


Seizing Opportunity: AMCP Nexus 2016 Offers Knowledge, Advancement and More

 

August 3, 2016 

“Healing is a matter of time, but it is sometimes also a matter of opportunity,” said the great Hippocrates, father of western medicine.

Opportunity, in fact, is a crucial element in the work that managed care pharmacy professionals engage in every day to improve the health, wellbeing and “healing” of millions of patients. We seize opportunities to find the right medicines for the right patients at the right time. ... Read more 


  


BRC Now Lets You Look It Up

 

July 13, 2016 

It was only ten years ago when biosimilars were so new that the New York Times described them as “so-called.” As late as five years ago newspapers put quotation marks around the term, as in “biosimilars.” At the time some still called them “follow-on” biopharmaceutics. ... Read more 


     


Is FDAMA Section 114 Finally Ready for Prime Time?

 

June 24, 2016 

Information is the life blood of managed care pharmacy. Of the “competent and reliable scientific” variety, that is.

Our profession operates best when we have broad access to the latest evidence-based data on the multitude of products coming to market today. We can plan, we can assess. With this information, managed care pharmacy professionals can help health care providers and patients select the right drug for the right patient at the right time, while making appropriate use of our scarce health care dollars. ... Read more 


     


Getting it straight with the updated AMCP Format!

 

May 19, 2016 

Using the best evidence possible to make informed health care decisions is a hallmark of managed care pharmacy. But making sense of the data often is no easy task, especially when it comes to analyzing pharmaceuticals and the value they bring to patients and the health care system... Read more 


     


CEO Susan Cantrell Addresses AMCP Annual Meeting

 

May 10, 2016 

New&Views announces a new monthly column by CEO Susan A. Cantrell, RPh, CAE, on breaking news and critical issues. Her first column presents her recent address―her first to the membership―at AMCP’s recent Annual Meeting.

“It is truly an honor to be standing before you today as the Academy’s new CEO. While new to the AMCP staff, I’ve been an observer and at times a participant in the terrific work of this organization. ..." Read more.